secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0002007919-25-000089
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ozekibart meets primary endpoint in chondrosarcoma; BLA submission planned Q2 2026
--------------------------------------------------------------------------------

- ChonDRAgon study achieved primary endpoint: 52% reduction in risk of progression or death (HR=0.479; p<0.0001); median PFS 5.52 vs 2.66 months.
- Disease control rate 54% (ozekibart) vs 27.5% (placebo); benefit consistent across IDH subgroups.
- CRC expansion cohort (n=26 evaluable): 23% ORR, 92% disease control rate in heavily pretreated patients.
- Ewing sarcoma expansion (n=25 evaluable): 64% ORR, 92% disease control rate; typical standard of care ORR 15-30%.
- One fatal hepatotoxicity event early in study; risk mitigated by excluding severe liver impairment and close monitoring; overall hepatic AEs 11.8% vs 4.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/0002007919-25-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791925000089/inhibrx-20251023.htm
  HTML page:      https://secwatch.observer/filing/0002007919-25-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer